29 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 14 Phase 4, 2 Not applicable, 1 Phase 1, 1 Phase 2.
By phase and status
Follow Eisai Korea Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
Filgotinib Maleate - Ulcerative Colitis | Phase 4 | Active not recruiting | Eisai Korea Inc. | 94 | 2025-06-11 | 2026-07-02 |
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
No Intervention - Alzheimer's Disease | | Recruiting | Eisai Korea Inc. | 3000 | 2025-02-24 | 2026-04-21 |
A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis
Filgotinib Maleate - Rheumatoid Arthritis | Phase 4 | Completed | Eisai Korea Inc. | 118 | 2024-10-22 | 2026-05-11 |
A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants
Non-interventional - Arthritis, Rheumatoid, Colitis, Ulcerative | | Recruiting | Eisai Korea Inc. | 2040 | 2024-02-27 | 2026-07-06 |
A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures
Perampanel - Epilepsy | Phase 4 | Completed | Eisai Korea Inc. | 125 | 2022-10-19 | 2025-03-07 |
A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea
Safinamide Mesilate - Parkinson Disease | Phase 4 | Completed | Eisai Korea Inc. | 201 | 2022-04-05 | 2024-09-23 |
A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients
Non-interventional - Endometrial Neoplasms, Endometrium | | Completed | Eisai Korea Inc. | 135 | 2021-06-25 | 2024-03-25 |
A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)
Equfina 50 mg - Parkinson Disease | | Completed | Eisai Korea Inc. | 702 | 2021-06-03 | 2025-06-22 |
A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer
Pariet - Stomach Ulcer, Duodenal Ulcer | | Completed | Eisai Korea Inc. | 676 | 2020-07-23 | 2022-11-22 |
Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
Nivolumab - Metastatic Breast Cancer | Phase 1 / Phase 2 | Unknown | Seoul National University Hospital | 90 | 2019-08-01 | 2021-09-08 |
A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants
Non-interventional - Liver Neoplasms, Carcinoma, Hepatocellular | | Completed | Eisai Korea Inc. | 658 | 2019-05-28 | 2023-01-09 |
Symbenda Post-Marketing Surveillance (PMS)
Lymphoma, Non-Hodgkin, Lymphocytic Leukemia | | Completed | Eisai Korea Inc. | 84 | 2018-07-04 | 2021-01-26 |
A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting
Usual care setting - Mild Cognitive Impairment | | Completed | Eisai Korea Inc. | 201 | 2018-06-22 | 2021-10-06 |
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
Eribulin mesylate - Locally Advanced or Metastatic Breast Cancer | | Completed | Eisai Korea Inc. | 340 | 2018-01-25 | 2019-01-25 |
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
Inflammatory Bowel Disease | | Completed | Eisai Korea Inc. | 40 | 2017-09-21 | 2020-03-10 |
Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
Arthritis, Rheumatoid | | Completed | Eisai Korea Inc. | 212 | 2017-09-11 | 2020-12-16 |
A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis
No Intervention - Multiple Sclerosis, Relapsing-remitting | | Completed | Eisai Korea Inc. | 172 | 2017-06-14 | 2022-05-09 |
Post-Marketing Surveillance of Lenvima in Korean Patients
Differentiated Thyroid Carcinoma (DTC) | | Completed | Eisai Korea Inc. | 132 | 2016-11-10 | 2021-10-07 |
A Study of Fycompa (Perampanel) in Korean Participants
Epilepsy | | Completed | Eisai Korea Inc. | 3692 | 2016-07-01 | 2021-08-09 |
Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization
Perampanel - Epilepsy | Phase 4 | Completed | Eisai Korea Inc. | 106 | 2016-05-03 | 2020-02-05 |
Showing 20 of 34. Sign in to see all of them.
Conditions studied
Alzheimer Disease (10) · Epilepsy (7) · Breast Neoplasms (4) · Arthritis, Rheumatoid (3) · Colitis, Ulcerative (3) · Dementia (2) · Neoplasm Metastasis (2) · Parkinson Disease (2) · Arthralgia (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Cognitive Dysfunction (1) · Crohn Disease (1) · Duodenal Ulcer (1)
Interventions
Donepezil (7) · Zonisamide (4) · eribulin (2) · perampanel (2) · Carbamazepine (1) · Nivolumab (1) · Population Groups (1) · Rabeprazole (1) · Topiramate (1)
Countries
South Korea (33) · China (1) · Philippines (1) · Singapore (1) · Taiwan (1) · Thailand (1) · United States (1)
Top investigators
Jihee Mun (6) · Doh Kwan Kim, PhD, M.D. (2) · Jiheed Mun (1)
Results publications
PMID 33827446, PMID 37890351, PMID 38910942, PMID 39105849, PMID 39320906, PMID 39540934